Applied Therapeutics Inc logo

Applied Therapeutics Inc

$ 0.93 -0.0174 (-1.83%) 08:08 PM EST
P/E:
At Loss
P/B:
4.66
Market Cap:
$ 44.82M
Enterprise V:
$ 838.00K
Volume:
66.65K
Avg Vol (2M):
442.18K
Also Trade In:
Volume:
66.65K
Market Cap $:
44.82M
PE Ratio:
At Loss
Avg Vol (2-Month):
442.18K
Enterprise Value $:
838.00K
PB Ratio:
4.66
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Applied Therapeutics Inc ( ) from 2019 to Dec 02 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Applied Therapeutics stock (APLT) PE ratio as of Dec 02 2022 is 0. More Details

Applied Therapeutics Inc (APLT) PE Ratio (TTM) Chart

To
Not Enough Data to Display

Applied Therapeutics Inc (APLT) PE Ratio (TTM) Historical Data

Total 898
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10
Applied Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-12-03 At Loss 2022-09-29 At Loss
2022-12-01 At Loss 2022-09-28 At Loss
2022-11-30 At Loss 2022-09-27 At Loss
2022-11-29 At Loss 2022-09-26 At Loss
2022-11-28 At Loss 2022-09-23 At Loss
2022-11-25 At Loss 2022-09-22 At Loss
2022-11-23 At Loss 2022-09-21 At Loss
2022-11-22 At Loss 2022-09-20 At Loss
2022-11-21 At Loss 2022-09-19 At Loss
2022-11-18 At Loss 2022-09-16 At Loss
2022-11-17 At Loss 2022-09-15 At Loss
2022-11-16 At Loss 2022-09-14 At Loss
2022-11-15 At Loss 2022-09-13 At Loss
2022-11-14 At Loss 2022-09-12 At Loss
2022-11-11 At Loss 2022-09-09 At Loss
2022-11-10 At Loss 2022-09-08 At Loss
2022-11-09 At Loss 2022-09-07 At Loss
2022-11-08 At Loss 2022-09-06 At Loss
2022-11-07 At Loss 2022-09-02 At Loss
2022-11-04 At Loss 2022-09-01 At Loss
2022-11-03 At Loss 2022-08-31 At Loss
2022-11-02 At Loss 2022-08-30 At Loss
2022-11-01 At Loss 2022-08-29 At Loss
2022-10-31 At Loss 2022-08-26 At Loss
2022-10-28 At Loss 2022-08-25 At Loss
2022-10-27 At Loss 2022-08-24 At Loss
2022-10-26 At Loss 2022-08-23 At Loss
2022-10-25 At Loss 2022-08-22 At Loss
2022-10-24 At Loss 2022-08-19 At Loss
2022-10-21 At Loss 2022-08-18 At Loss
2022-10-20 At Loss 2022-08-17 At Loss
2022-10-19 At Loss 2022-08-16 At Loss
2022-10-18 At Loss 2022-08-15 At Loss
2022-10-17 At Loss 2022-08-12 At Loss
2022-10-14 At Loss 2022-08-11 At Loss
2022-10-13 At Loss 2022-08-10 At Loss
2022-10-12 At Loss 2022-08-09 At Loss
2022-10-11 At Loss 2022-08-08 At Loss
2022-10-10 At Loss 2022-08-05 At Loss
2022-10-07 At Loss 2022-08-04 At Loss
2022-10-06 At Loss 2022-08-03 At Loss
2022-10-05 At Loss 2022-08-02 At Loss
2022-10-04 At Loss 2022-08-01 At Loss
2022-10-03 At Loss 2022-07-29 At Loss
2022-09-30 At Loss 2022-07-28 At Loss

Applied Therapeutics Inc (APLT) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.